Please assess the completion status of the following clinical trial:

Trial Title: Erenumab For Treatment of Hemicrania Continua

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Adults over the age of 18-66~* At least a 12 month history of hemicrania continua (unremitting subtype) according to International Classification of Headache Disorders, 3rd Edition (ICHD-3)1~* Previous or current complete response to indomethacin~* Stable preventive treatment for at least 2 months and no anticipated need to adjust/add current headache prevention treatment~Exclusion Criteria~* Nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used for at least 1 week~* Pregnant or lactating subjects~* Use of barbiturate or opioid \>6 days per month; history of chronic migraine~* History of previous trigeminal-autonomic cephalalgia~* History within previous 2 months of interventional procedure for headache (occipital or other extracranial nerve block, sphenopalatine ganglion block, cervical facet block, facet rhizotomy)~* History of cranial nerve/rhizolysis~* Botulinumtoxin injection with previous 4 months~* Parenteral infusion of or oral corticosteroid use for more than 3 days within 4 weeks prior to screening phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with Erenumab (Type: EXPERIMENTAL): Subjects diagnosed with hemicrania continua will receive single dose of Erenumab

Based on this trial design, predict the completion outcome and termination type (if applicable).